Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.

Background Survivin is a small protein inhibitor of apoptosis and a tumor associated antigen. Survivin expression in multiple myeloma is associated with poor prognosis, disease progression, and drug resistance. The CD4+ response against survivin remains uncharacterized.